A 60-year-old woman was referred to our hospital with swelling of the right leg. After surgery, leiomyosarcoma of the right leg was diagnosed. Computed tomography showed two hypovascular masses in the pancreatic body and tail that were heterogeneously enhanced compared with the pancreatic parenchyma. On endoscopic ultrasonography, the tumors in the pancreatic body and tail both exhibited regular margins and were visualized as well-circumscribed masses with uneven interiors. Distal pancreatectomy was performed under a presumptive diagnosis of metastatic pancreatic leiomyosarcoma diagnosed based on the findings of EUS-FNA. On laparotomy, peritoneal washing cytology yielded negative results, and no dissemination was observed. Ultimately, metastatic pancreatic leiomyosarcoma was histologically diagnosed.
Introduction
The incidence of metastatic pancreatic tumors has been reported to be only 1.6-3% (1) . Lung, renal and gastric cancers have been reported to be the most common primary tumors associated with pancreatic metastasis (2) (3) (4) . Leiomyosarcoma is a rare source of pancreatic metastasis compared to these tumors. Pancreatic metastatic tumors are usually seen in patients with disseminated disease and metastases in other organs and are primarily detected on autopsy. Solitary metastasis to the pancreas is thus extremely rare. To the best of our knowledge, only 25 cases have been reported to date (1, 2, . In addition, no cases of multiple metastatic leiomyosarcoma in the pancreas without dissemination or other metastatic organs have been previously reported. We herein report the first case of multiple metastatic leiomyosarcoma in the pancreas without dissemination or other metastatic organs and review previously published reports.
Case Report
A 60-year-old woman was referred to our hospital with swelling of the right leg. The mass in the right leg measured 50 mm in maximum diameter and was heterogeneously enhanced on computed tomography (CT) (Fig. 1a) . Leiomyosarcoma of the right leg was diagnosed following examinations performed in the department of orthopedic surgery. In addition, preoperative 18 F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) showed strong accumulation in the pancreatic body and tail (Figs.1b-d) . Surgery of the right leg revealed the presence of leiomyosarcoma. Three weeks after surgery, the patient was referred to our department of internal medicine for further examinations of the pancreatic masses. All laboratory values were normal, including the serum levels of carbohydrate antigen 19-9 and carcinoembryonic antigen, with the exception of slight elevations in the levels of amylase (153 ng/dL), elastase-1 (726 ng/dL) and C-reactive protein (0.55 mg/dL). CT showed two b a hypovascular masses measuring 30 mm and 70 mm in maximum diameter in the pancreatic body and tail that were heterogeneously enhanced compared with the pancreatic parenchyma. In addition, necrotic and cystic changes were seen in both masses (Fig. 2a) . Magnetic resonance imaging (MRI) showed hyperintensity of the pancreatic masses on T2-weighted imaging and decreased diffusion on diffusionweighted imaging. The main pancreatic duct was stenosed, b a c measuring 10 mm, in the pancreatic body, and dilatation measuring 5 mm in maximal diameter was seen in the tail on magnetic resonance cholangiopancreatography (MRCP) (Fig. 2b) . On endoscopic ultrasonography (EUS), the tumors in the pancreatic body and tail both exhibited regular margins and were visualized as well-circumscribed masses with uneven interiors. The tumors were not continuous with each other. On contrast-enhanced EUS using Sonazoid (DaiichiSankyo, Tokyo, Japan), marked enhancement was observed from the early stage of enhancement, and an anechoic region suggesting the presence of necrosis was seen in the interior. Samples obtained from the pancreatic body and tail masses using EUS-guided fine needle aspiration (FNA) revealed histopathological proliferation of atypical spindleshaped cells. Immunohistochemical staining demonstrated that these cells were positive for α-SMA and vimentin and negative for CD34 and desmin (Figs. 3, 4 ). These findings were extremely similar to the histological findings of leiomyosarcoma in the leg. Distal pancreatectomy was performed under a presumptive diagnosis of metastatic pancreatic leiomyosarcoma. On laparotomy, peritoneal washing cytology yielded negative results, and no dissemination was observed. In the resected samples, elastic hard tumors with a smooth surface were identified in the pancreatic body as well as the pancreatic tail. The sections also exhibited solid, grayish-white tumors with capsules. The interior contained a cavity suggestive of necrosis (Fig. 5) . Histopathologically, hematoxylin and eosin (HE) staining showed fascicular proliferation of atypical spindle-shaped cells with partial invasion into the pancreatic duct. Immunostaining revealed the tumors to be CD34-negative, desmin-negative, α-SMApositive and vimentin-positive. As these findings were very similar to those of the leiomyosarcoma in the thigh, metastatic pancreatic leiomyosarcoma was diagnosed (Fig. 6) . No signs of recurrence have been observed as of one year postoperatively.
Discussion
Metastatic pancreatic tumors are rare. In a series of 4,995 adult autopsies, Adsay et al. reported only 81 cases (1.6%) of metastatic pancreatic tumors (1) . Most of these cases involved disseminated carcinoma and other metastatic organs; therefore, isolated pancreatic metastases are even more rare. Roland et al. (26) reported that only 27 of 1,357 patients (2%) with solitary pancreatic masses had metastatic pancreatic tumors, only four of which were resected. In addition, Nakamura et al. (2) reviewed the autopsy records and pathological features of 103 cases of metastatic pancreatic tumors and found that gastric cancer was the most common primary tumor site (20%), followed by the lungs (18%) and extrahepatic bile duct (13%), with leiomyosarcoma representing a rare primary tumor (<2%). To the best of our knowledge, metastatic pancreatic leiomyosarcoma has been reported previously in only 25 cases (1, 2, 5-25). Moreover, isolated metastatic pancreatic leiomyosarcoma without dissemination or metastases in other organs is extremely rare. Table shows a review of the 25 previously reported cases of metastatic pancreatic leiomyosarcoma. Among these cases, the mean patient age at the time of diagnosis was 51.7 years (range: 39-79 years) and the ratio of men to women was 6:14. The uterus was the most common primary tumor site (n=7), followed by the legs (n=5), retroperitoneum (n=3) and gastrointestinal tract (n=3). The pancreatic head was the most frequent site of metastasis, and almost all lesions represented solitary metastatic pancreatic leiomyosarcoma. On the other hand, a few cases involved multiple metastases to the pancreas. However, these cases also involved other metastatic organs or dissemination. In the present case, despite the presence of multiple metastatic pancreatic lesions, no other metastatic organs or dissemination were identified. This may represent the first report of such a case.
When metastatic tumors of the pancreas are solitary, making a preoperative differential diagnosis between primary pancreatic tumor and metastatic tumor remains challenging. The symptoms of pancreatic metastatic tumors commonly include obstructive jaundice, abdominal pain and body weight loss, while new-onset diabetes is observed in cases of primary pancreatic tumors (19, 27) . However, pancreatic metastatic tumors are frequently asymptomatic and detected only incidentally during follow-up. On the other hand, imaging techniques such as CT and MRI may support the clinical suspicion of metastatic tumors to the pancreas, particularly when multiple lesions are detected in the pancreas (28) . Z'graggen et al. (27) reported the cases of 10 patients with isolated metastases in the pancreas, among whom the tumors were initially misdiagnosed as pancreatic cancer in seven of the cases. Detailed anamnesis, clinical aspects, FNA, oncogene analyses such as K-ras mutation analyses (29) and imaging findings are thus all important for the accurate diagnosis and treatment of pancreatic metastasis (30) .
In general, the time between diagnosis of primary cancer and detection of pancreatic metastasis varies widely, ranging from 0.5 to 2 years in patients with lung cancer, 7.5 years in patients with breast cancer and 10 years in patients with renal cell carcinoma (31) . Likewise, in reported cases of leiomyosarcoma, the interval to metastasis or recurrence varies widely from approximately one to 10 years. As such, cases of slow-growing pancreatic metastases have been reported; however, the details of these metastases have not been elucidated.
Regarding the prognosis of metastatic pancreatic tumors, Raddy et al. (32) reported a 5-year survival rate of 36-88% in patients undergoing resection, representing a more favorable rate than that of patients with pancreatic ductal adenocarcinoma, with a prognosis that improves with increasing time to recurrence. A similar pattern has been observed for leiomyosarcoma, with a favorable prognosis being reported for patients undergoing resection.
In conclusion, we herein report the first case of multiple metastatic leiomyosarcoma to the pancreas without dissemination or other metastatic organs. In cases of solitary metastasis with no other distant metastases or dissemination, active resection is considered important for achieving a favorable prognosis in the absence of other effective anticancer agents, even in cases of multiple tumors, such as the present case.
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